| Clinical data | |
|---|---|
| Trade names | Ubeslo |
| Other names | TA-8995; AMG-899 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C32H31F9N4O5 |
| Molar mass | 722.609 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Obicetrapib, sold under the brand name Ubeslo, is used for the treatment of dyslipidemia. It is a CETP inhibitor. Obicetrapib is a lipid-modifying agent that blocks a blood protein called CETP, thereby lowering the level of LDL cholesterol.
The most common side effects include hypertension, dizziness, headache, diarrhea, and abdominal pain.
Obicetrapib is indicated in adults with primary hypercholesterolemia (heterozygous familial and non familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in people unable to reach low density lipoprotein cholesterol (LDL C) goals with the maximum tolerated dose of a statin; or alone or in combination with other lipid-lowering therapies in people who are statin intolerant, or for whom a statin is contraindicated.
Obicetrapib was initially developed by Amgen as AMG-899 and was abandoned in 2017. In 2020, Amgen licensed the drug to NewAmsterdam Pharma. In 2022, NewAmsterdam Pharma licensed the drug to Menarini Group.
In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%).
Obicetrapib's ability to lower LDL cholesterol (“bad” cholesterol) compared with placebo was observed in two 52-week, randomized, double-blind, placebo-controlled studies in adults with high cholesterol and/or mixed dyslipidemia who were already receiving the maximum tolerated cholesterol-lowering treatment.
Obicetrapib was authorized for medical use in the European Union in September 2026.
Obicetrapib is the International nonproprietary name.
Obicetrapib is sold under the brand name Ubeslo.